Lexaria Bioscience Corp (LEXXW)

Etorro trading 970x250
Lexaria Bioscience Corp (LEXXW) Logo

About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Address: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

Lexaria Bioscience Corp News and around…

Latest news about Lexaria Bioscience Corp (LEXXW) common stock and company :

Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
22 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
21 Apr, 2022 FinancialContent
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
21 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
20 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
19 Apr, 2022 FinancialContent
Lexaria Commences Multi-Week Human Clinical Hypertension Study
19 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 19, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has begun its multi-week human clinical hypertension study.

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
14 Apr, 2022 FinancialContent

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration

Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
13 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
12 Apr, 2022 FinancialContent
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
12 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
11 Apr, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altria").

Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
16 Mar, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
15 Mar, 2022 FinancialContent

KELOWNA, BC / ACCESSWIRE / March 15, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that the first phase of its epilepsy research program EPIL-A21-1 is beginning this week, and the DehydraTECHTM-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory engaged to complete this research program.

Lexaria Granted Important New Oral Nicotine Patent
08 Mar, 2022 FinancialContent

Newest granted patent expands worldwide patent portfolio to 24

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
02 Feb, 2022 FinancialContent

DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
27 Jan, 2022 FinancialContent
Lexaria Provides Annual Letter From the CEO
27 Jan, 2022 FinancialContent
IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka
20 Jan, 2022 Yahoo! Finance

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently appeared on the EDGE Podcast, a series focused on providing the business owner's playbook about the inner game of building a successful business and giving listeners the e

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
18 Jan, 2022 FinancialContent
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
29 Dec, 2021 FinancialContent
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
16 Dec, 2021 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
14 Dec, 2021 FinancialContent
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
14 Dec, 2021 FinancialContent
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
08 Dec, 2021 FinancialContent
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference
06 Dec, 2021 Yahoo! Finance

Detroit, Michigan--(Newsfile Corp. - December 6, 2021) - Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/. About the Benzinga Global Small Cap Conference ...

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
01 Dec, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
10 Nov, 2021 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
03 Nov, 2021 FinancialContent
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
03 Nov, 2021 FinancialContent
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
01 Nov, 2021 FinancialContent

Lexaria Bioscience Corp (LEXXW) is a NASDAQ Common Stock listed in

970x250